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The Use of Race in Medical Artificial Intelligence 
Priya Desai* 
I. INTRODUCTION 
Recently, the use of medical algorithms and machine learning (ML) in health 
care has flourished as the collection of mass health data has become more 
normalized. Also called “black-box medicine,” the use of artificial intelligence (AI) 
in medicine has led to medical innovation and efficiency. The goal of this technology 
is to improve the health care system and people’s health overall by helping to identify 
risk and allocate resources. But at what cost? A critical issue hidden behind medical 
AI is the use of race in these algorithms. While society’s understanding of race has 
advanced significantly over time, such understanding has not led to coherent 
guidance on the use of race in medicine.1 One of several ways in which race is 
becoming embedded into medical AI involves diagnostic algorithms that “correct” 
their outputs based on a patient’s race or ethnicity.2 Additionally, inserting race into 
the data that trains these algorithms promotes race-based medicine.3 
In this Note, I will first examine the process by which medical algorithms and 
AI are created and how they work. Next, I will explain the use of race in medical 
algorithms. I will focus primarily on the problems that arise when using race in 
medical AI. Furthermore, I will advocate for policy considerations deterring the use 
of race as a proxy for other social determinants of health in medical algorithms. 
Alternative factors such as socioeconomic status, geographic area, education, and 
other social determinants of health should be taken into consideration when training 
medical AI. Lastly, I will describe the current regulatory landscape for medical AI 
and conclude by advocating for legislation and regulations that may help to alleviate 
racial bias in medical AI. 
                                                          
* Priya Desai is a J.D. Candidate for the Class of 2022 at the University of Pittsburgh School of 
Law. She is the Managing Editor of the Pittsburgh Journal of Technology Law and Policy. She is also 
pursuing the Health Law Certificate at Pitt Law. Thank you to Professor Mary Crossley for all of her 
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1 Darshali A. Vyas et al., Hidden in Plain Sight—Reconsidering the Use of Race Correction in 
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A. What is Medical AI? 
While AI has been defined in several ways, broadly, AI is the “science and 
engineering of making intelligent machines, especially intelligent computer 
programs.”4 Within the field of AI, ML encompasses the creation of algorithms to 
learn, recognize patterns, and follow data.5 With respect to their design, algorithms 
can be “locked” or can continuously learn and adjust with the addition of new data 
in order to optimize their real-time effectiveness.6 
Medical AI is one example of evidence-based medicine, which involves the use 
of past data to support clinical decision-making.7 Traditionally, statistical methods 
have accomplished this feat by describing patterns within data as mathematical 
equations like a line of best fit; however, ML enables us to bring light to complex 
associations that cannot be represented as equations.8 For instance, neural networks, 
a form of ML, portray data through an abundance of interconnected neurons, similar 
to the human brain.9 Thus, ML systems can approach problem-solving and decision-
making in the same way that a clinician would—by attentively considering evidence 
to reach informed decisions.10 However, in contrast to an individual clinician, neural 
networks can simultaneously examine and quickly process an almost infinite amount 
of inputs.11 In addition, these machines can learn from each additional case in a 
cumulative manner. Thus, they can come in contact with more cases than a clinician 
could see in their lifetime, in a matter of minutes.12 It is worth noting that medical 
algorithms, as a decision support tool, existed before they incorporated AI. Medical 
algorithms are much more powerful and can incorporate more data and ML with the 
addition of AI. 
                                                          
4 Timo Minssen et al., Regulatory Responses to Medical Machine Learning, 7 J.L. & BIOSCIENCES 
1, 2 (2020). 
5 Id. 
6 Id. 
7 Varun H. Buch et al., Artificial Intelligence in Medicine: Current Trends and Future Possibilities, 
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B. How Does Medical AI Work? 
First, programmers feed structured data to computer systems.13 Data is 
structured when each data point is labeled or annotated in a way that makes the 
information recognizable to the algorithm.14 Once the algorithm is exposed to a 
sufficient amount of data points and their labeling conventions, the performance of 
the algorithm is evaluated to make sure it is reaching accurate conclusions, in the 
same way that tests are given to students.15 These algorithm evaluations typically 
comprise of inputting test data that programmers have the answers to, so that they 
can observe the algorithm’s ability to ascertain the right answer.16 Based on results 
from the evaluation process, the algorithm can be adapted, fed additional data, or put 
to use in the real world.17 AI algorithms are capable of doing tasks that require human 
intelligence, such as pattern and speech recognition, image analysis, and decision 
making.18 
C. How is Medical AI Being Used? 
Medical AI has a wide array of uses throughout the health care system, 
including in administrative, custodial, caregiving, research, imaging, and diagnosis 
settings. Hospitals and physician offices will soon rely on AI that automates routine 
office tasks like making appointments, billing patients, and requesting 
reimbursement.19 Language processing technology should improve note-taking and 
reduce the need for scribes.20 Additionally, health care facilities will make use of 
service robots such as laundry-pulling driverless vehicles, food service robots, and 
room-cleaning machines.21 Finally, caregiving AI includes robotic cribs devised to 
help babies sleep better, voice companions that will converse and play games with 
                                                          
13 Daniel Greenfield, Artificial Intelligence in Medicine: Applications, Implications, and 
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seniors, robot companions for the elderly, and robots that can pick up and move 
people.22 
In terms of research, pharmaceutical companies are relying on AI to speed up 
drug development and have tasked such AI with finding patterns in clinical data.23 
When it comes to imaging, pathology, and radiology, AI is extremely skilled at 
recognizing patterns, thus making it a good tool for reading screenings for conditions 
like skin cancer, colon cancer, evidence of stroke, and pneumonia.24 Lastly, a 
significant application of AI involves its ability to improve diagnosis by using 
predictive diagnosis methods.25 For example, predictive diagnosis is found in the use 
of streams, an algorithm that uses Google’s DeepMind and has been trained on over 
a million patient records.26 This technology signals clinicians about acute kidney 
disease in patients.27 
D. Benefits of Medical AI 
The benefits to using AI are almost limitless. One of the most significant 
benefits to using medical AI involves the idea of democratizing expertise.28 There 
are overwhelming differences in the quality and degree of care patients receive 
depending on the context in which they get care.29 Medical AI aims to decrease this 
variation by evening out the playing field, meaning it will enable an abundance of 
low-resource providers to provide care equivalent to the that of an expert or specialist 
in the field.30 In regards to patient care, medical AI allows for the use of complex 
relationships to recommend various treatment options and to improve existing 
diagnosis and treatment options.31 Medical AI is the next step towards personalized 
medicine, as it can give diagnoses or preventive recommendations based on 
                                                          
22 Id. at 144. 
23 Id. 
24 Id. at 145. 
25 Id. at 146. 
26 Id. at 147. 
27 Id. 
28 W. Nicholson Price II, Medical AI and Contextual Bias, 33 HARV. J.L. & TECH. 66, 73 (2019) 
[hereinafter Price II, Medical AI and Contextual Bias]. 
29 Id. 
30 Id. 
31 W. Nicholson Price II, Black-Box Medicine, 28 HARV. J.L. & TECH. 420, 435 (2015) [hereinafter 
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individual patient data.32 These machines can detect unseen patterns and 
relationships.33 For example, “a black-box medicine prediction might be that patients 
who have a set of linked variations in a dozen different genes, smoke, and have 
middling-high blood pressure might predictably respond better to one medication 
than another—even if those factors could not be explained or even explicitly 
identified.”34 
In terms of drug discovery and development, medical AI can help determine 
when already-approved drugs can be prescribed or used for a new purpose.35 Another 
benefit of medical AI includes the automation of routine tasks.36 This type of medical 
AI is least likely to be riddled with bias and will be extremely helpful in underserved 
areas where health care facilities lack sufficient resources to keep up with routine 
tasks.37 Finally, unpublished investigations have analyzed algorithms used in “public 
health, criminal justice and education to human decision-making and found that the 
[ML] systems were biased—but less so than people.”38 
E. Consequences of Medical AI 
While the benefits of medical AI seem extremely promising, it is crucial to note 
that there are some negative consequences that may come with its use as well. 
Medical AI is usually trained in high-resource settings such as university medical 
centers or extremely sophisticated hospital systems.39 These facilities tend to have 
both reliable data and knowledgeable specialists that are experts in their fields.40 
Critically, many high-resource hospitals show patient populations heavily skewed 
towards upper-class, white communities.41 Patient population differences such as 
ancestral origin, genetic variation, socioeconomic status, etc. can guide treatment in 
various ways.42 Therefore, if high-resource hospitals have distinctly different patient 
                                                          
32 Id. 
33 Id. 
34 Id. at 430. 
35 Id. at 435. 
36 Price II, Medical AI and Contextual Bias, supra note 28, at 73. 
37 Id. at 72. 
38 Heidi Ledford, Millions of Black People Affected by Racial Bias in Health-Care Algorithms, 
NATURE (Oct. 24, 2019), https://www.nature.com/articles/d41586-019-03228-6. 
39 Price II, Medical AI and Contextual Bias, supra note 28, at 66. 
40 Id. at 67. 
41 Id. at 93. 
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populations, then medical AI that learns from data representative of high-resource 
populations and then distributed for use in diverse settings may run into issues due 
to those patient population differences.43 This phenomenon is known as contextual 
bias.44 
Some treatments are successful when executed by practitioners with expertise 
and strong support staff but fail if carried out without those resources.45 ML trained 
in high-resource settings may learn to select treatments that are only successful due 
to the fact that they were performed in those high-resource settings.46 Thus, when 
those algorithms are utilized in low-resource settings, quality of care may diminish.47 
In addition, training medical AI in high-resource facilities could lead the algorithm 
to prefer more costly procedures, leading to increased health care expenditures and 
financial burden on patients.48 
III. THE USE OF RACE IN MEDICAL AI 
An algorithm used by hospitals nationwide has been “systematically 
discriminating against black people.”49 The algorithm was designed to allocate health 
care to patients and has been put to use by hospitals and insurers in order to manage 
care for an estimated 200 million people throughout the country every year.50 The 
purpose of the AI was to pinpoint a subset of patients who needed supplementary 
care for complex health needs before the condition became urgent and expensive.51 
A study published in Science found that the algorithm was “less likely to refer 
black people than white people who were equally sick to programs that aim to 
improve care for patients with complex medical needs.”52 Essentially, the algorithm 
was assigning risk scores to patients based on total health care costs accrued in one 
                                                          
43 Id. at 92–93. 
44 Id. at 68. 
45 Id. at 95. 
46 Id. 
47 Id. 
48 Id. at 97. 
49 Ledford, supra note 38. 
50 Id. 
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year.53 Researchers explain that this assignment appears reasonable at first glance 
because higher health-care costs are typically associated with more health needs.54 
However, while the average black person in the data set had comparable health care 
expenses to the average white person, the data actually uncovered that the average 
black person was considerably more sick than the average white person.55 Therefore, 
people who self-identified as black were assigned lower risk scores than equally sick 
white people since their health care costs were lower.56 Consequently, black people 
had to be sicker than white people in order to be recommended additional care.57 The 
study also concluded that while 17.7% of patients that the algorithm assigned to 
receive extra care were black, that number should have been 46.5% if the algorithm 
was not biased against black people.58 
The racial differences apparent in sets of data most likely emulates the effects 
of racism, meaning “the experience of being black in America rather than being black 
itself.”59 These effects can manifest in the form of toxic stress and physiological 
impacts on the body.60 In these situations, relying on data without recognizing that 
the data was racially skewed or adjusting risk scores based on race ends up deterring 
clinicians from providing necessary care to minority patients, and thus reinforces 
inequity into the health care system.61 
If foundational data that train medical AI embody racism that is built into social 
structures, then the use of these technologies for diagnostic and treatment purposes 
can ingrain racism into both practice and policy.62 When tools like AI influence 
serious determinations, whether medically or in other contexts, they exacerbate 
systemic inequity.63 The issues arising from biased data and inadequate testing of the 
data can become more extensive as models become more convoluted and as biases 







59 Vyas et al., supra note 1, at 879. 
60 Id. 
61 Id. 
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can get harder to foresee or recognize.64 An even greater challenge in trying to 
prevent biased results grounded in social inequity is when sensitive information like 
ethnicity is correlated with variables that appear to be neutral, like home address or 
area code to a phone number.65 In these situations, eliminating the sensitive 
information will not stop the machine from reaching biased conclusions.66 
In order for AI technology to adequately take into account effects of racism and 
the experience of being black in America, adjustments should be made based on 
social determinants of health, rather than race itself. Social determinants of health 
include healthcare access and quality, education access and quality, social and 
community contexts, economic stability, and neighborhood and built environment.67 
Algorithms must not confuse patients’ races with their socioeconomic status or 
access to health care.68 These are the factors that should be taken into consideration 
when medical AI is both being trained and being implemented in the real world. If 
social determinants of health were factored into medical AI explicitly, they would 
allow for diagnosis and treatment decisions based on actual elements that contribute 
to health outcomes, rather than basing them on race, which is a social construct and 
cannot be directly linked to health outcomes. 
Contextual bias that is propagated by the use of medical AI also leads to health 
care disparities. Instead of bias originating from issues in the fundamental data or 
bias that arises from health algorithms reflecting racial or gender biases that already 
exist in health care, contextual bias stems from the process of transferring algorithms 
from one context to another.69 For example, voice recognition AI tends to be 
unsuccessful when interpreting accented voices. Similarly, data sets representative 
of skin lesions used to teach dermatological AI to identify melanomas lack images 
from patients with darker skin.70 Thus, shifting the use of the AI from a high-resource 
area to an underserved population will not produce adequate or effective results. 
                                                          
64 Miriam C. Buiten, Towards Intelligent Regulation of Artificial Intelligence, 10 EUR. J. RISK REG. 
41, 53 (2019). 
65 Id. 
66 Id. 
67 Social Determinants of Health: Know What Affects Health, CTR. FOR DISEASE CONTROL & 
PREVENTION (Mar. 10, 2021), https://www.cdc.gov/socialdeterminants/about.html. 
68 Nicoletta Lanese, Racial Bias is Baked Into Algorithms Doctors Use to Guide Treatment, 
LIVESCIENCE (June 29, 2020), https://www.livescience.com/racial-bis-health-care-algorithms.html. 
69 Price II, Medical AI and Contextual Bias, supra note 28, at 67–68. 
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A critical issue with translating algorithms developed in high-resource facilities 
to lower-resource settings is that those algorithms are likely to make decisions that 
are flawed in those lower-resource settings.71 This problem can manifest in two 
forms. First, discrepancies in diagnoses and treatment suggestions can arise due to 
the contrasting patient populations.72 Second, differences in suggested treatments can 
arise due to treatment rankings whose effectiveness changes with available medical 
resources.73 Unfortunately, conditions where medical AI has a high probability to 
face issues are exactly the same conditions where programmers are missing data 
necessary to enhance the quality of care—low resource communities.74 
In low-resource settings, we cannot presume that health care professionals will 
have sufficient knowledge and resources to identify and correct the flawed 
suggestions medical AI may make when its decision-making skills translate 
inadequately to the low-resource setting.75 Additionally, it is doubtful that low-
resource facilities possess adequate resources to address legal compliance issues like 
Health Insurance Portability and Accountability Act (HIPAA) regulations, in the 
same way that it is doubtful for these facilities to spare resources to comply with 
technological requirements for data infrastructure in order to partake in 
representative research.76 
IV. CURRENT REGULATIONS FOR MEDICAL AI 
The Federal Food, Drug, and Cosmetics Act (“FD&C Act”) gives the Food and 
Drug Administration (FDA) authority to regulate “medical devices.”77 The definition 
of a “medical device” is relatively broad and thus includes several forms of medical 
AI.78 In addition, the FDA has issued proposed regulatory guidance for Software as 
a Medical Device (SaMD) and regulatory direction with respect to clinical decision 
support software under the 21st Century Cures Act (“Cures Act”).79 The FDA has 
                                                          
71 Id. at 91. 
72 Id. 
73 Id. 
74 Id. at 100. 
75 Id. at 104. 
76 Id. at 83. 
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not published any official requirements or regulations regarding the quality and 
source of data used to develop medical AI.80 
Under the FD&C Act, FDA regulates medical devices using a risk-based 
classification system.81 All devices must follow registration, listing, and adverse-
event-reporting obligations.82 Class I devices are low-risk and therefore are subject 
only to those obligations.83 Class III devices are considered high-risk, so they must 
follow the premarket-approval pathway (PMA).84 This pathway requires developers 
to perform clinical trials and demonstrate safety and efficiency to the FDA.85 Finally, 
Class II devices are moderate-risk and can be approved by following the PMA 
pathway mentioned above or by following the 510(k) guidelines and establishing 
that the device is comparable to an already-approved device using.86 A challenge 
with the current classification system and regulating medical AI is that it is difficult 
to identify and quantify the risk associated with medical AI, thus making it a bad fit 
for the FDA’s existing regulatory scheme. 
To qualify as a medical device that must be regulated, a product must be 
“intended for use in the diagnosis of disease or other conditions, or in the cure, 
mitigation, treatment, or prevention of disease, in man or other animals.”87 Most 
medical AI technologies are intentionally designed “. . . for use in the diagnosis, 
cure, treatment, or mitigation of disease or other conditions in humans . . .” and 
therefore meet the intent element of the definition.88 Regardless of whether the FDA 
can regulate medical AI as devices under existing law, it can generally regulate 
medical AI as accessories to medical devices, “. . . such as monitors, special-purpose 
medical computers, or wearable medical devices . . . ,” which unquestionably meet 
the FDA’s definition of a device.89 Nevertheless, whether FDA truly has the 
authority to regulate complex medical AI is still unsettled.90 For many years, the 
                                                          
80 Id. at 85. 
81 W. Nicholson Price II, Regulating Black-Box Medicine, 116 MICH. L. REV. 421, 438 (2017) 






87 Id. at 439. 
88 Id. 
89 Id. at 440. 






T H E  U S E  O F  R A C E  
Volume XXI – Summer 2021 ● ISSN 2164-800X (online) 










FDA has asserted that it does not regulate the practice of medicine, and it made this 
position explicit when the FD&C Act was passed.91 Therefore, insofar as the use of 
medical AI to make diagnoses and treatment recommendations is considered the 
practice of medicine, the FDA’s distinction between devices and the practice of 
medicine may not be so clear-cut.92 
It is worth noting that under-regulation of medical AI may become a prominent 
issue under the existing FDA regulatory system, because algorithm developers are 
the only people with the requisite knowledge regarding how the algorithm was 
trained.93 Consequently, creators of the technology may be incentivized to understate 
possible problems with the model in order to receive FDA approval without 
difficulty.94 This means that any biases or errors that existed during the development 
of the model may not be picked up by the current FDA regulatory processes.95 
In terms of the future for AI regulation, the FDA is in the process of creating 
the National Evaluation System for Health Technology (NEST).96 The goal of NEST 
is “to generate evidence across the total product lifecycle of medical devices by 
strategically and systematically leveraging real-world evidence, and applying 
advanced analytics to data tailored to the unique data needs and innovation cycles of 
medical devices.”97 This development may play a role in an attempt to design a more 
flexible approach to regulating AI. Moreover, the FDA has acknowledged the utility 
of digital health products and AI by issuing a Digital Health Innovation Action Plan 
that “proposed new guidance, increased in-house expertise through hiring, and a 
more flexible approach to approving software products.”98 
It is evident from the patchwork of regulatory guidance and proposals that the 
FDA’s work to create uniform standards for regulating AI, and medical AI 
specifically, is far from over. The procedure currently in place is not ideal for 
algorithms and models due to its static nature, and the system does nothing to prevent 
racial biases from becoming entrenched in medical AI systems. Furthermore, the 
“medical devices” versus “practice of medicine” distinction is becoming less clear 
                                                          
91 Id. 
92 Id. at 441–42. 
93 Id. at 457. 
94 Id. 
95 Id. 
96 Id. at 464. 
97 Id. 
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as the days go by, thus clouding developers’ abilities and incentives to create 
groundbreaking technology. Overall, there is more that can be done to prevent 
systemic racism from being exacerbated by medical algorithms, while still retaining 
incentives for developers to create AI. 
V. PROPOSED LEGISLATION AND REGULATIONS 
Typically, developers of devices use clinical trials and comparative 
effectiveness trials to decide when to start implementing new medical technologies 
into the real world; however, these methods do not perform adequately to assess the 
quality of many sophisticated medical algorithms.99 Information about how medical 
algorithms are created is materially different from clinical-trial data that providers 
and insurers are used to.100 Plus, developers of medical AI tend to hide information 
about their algorithms in order to maintain competitive advantage over other 
developers.101 Even when facilities learn how the AI functions from their own 
personal experiences, providers are usually barred from publicizing their knowledge 
through nondisclosure agreements levied by the developers.102 In order to address 
these obstacles, along with the issues of contextual and racial bias in medical AI, the 
government should invest in public data infrastructure, which can force developers 
to rely on representative data when training medical AI.103 
In terms of infrastructure for data, the government should provide “computer 
servers, personnel, standards and procedures that enable data be collected, controlled 
for quality, and made available at lower resource settings.”104 Grants aimed at 
assisting low-resource facilities to purchase adequate computer systems and hire data 
personnel could completely alleviate the data-procurement obstacle that low-
resource settings face.105 Additionally, the government should set uniform 
specifications for electronic health records so that they would not be in a variety of 
different formats like they are currently.106 Also, the government can add a research 
                                                          
99 Price II, Regulating Black-Box Medicine, supra note 81, at 434. 
100 Id. at 436. 
101 Id. 
102 Id. 
103 Price II, Medical AI and Contextual Bias, supra note 28, at 100–01. 
104 Id. at 107–08. 







T H E  U S E  O F  R A C E  
Volume XXI – Summer 2021 ● ISSN 2164-800X (online) 










exemption to HIPAA to simplify the legal compliance process for low-resource 
facilities to collect and obtain data.107 
The value of data collected through a public infrastructure is that it can better 
reflect the quality and type of care that patients actually encounter.108 If high-quality 
data are gathered from an array of patient populations, the apprehension regarding 
the translation of medical AI to diverse patient populations diminishes.109 Plus, if 
data are gathered from a variety of care settings, such as community hospitals, that 
data can be more representative of resources accessible in that setting, the kinds of 
practices adopted, treatments that are commonly administered, and the health 
outcomes that arise.110 NIH’s “All of Us” initiative is an illustration of this type of 
proposal. Through the program, NIH intends to collect comprehensive health 
information that consists of genetic sequences, treatments, and outcomes from a 
million Americans. Imperatively, the sample population is expected to be 
representative of the U.S. population.111 
Despite this push for publicly funded data infrastructure, representative datasets 
do not necessarily have to be funded by the government. One idea is to combine 
“private spending on infrastructure for data with private acquisition of data.”112 Thus, 
developers could supply low-resource medical facilities with infrastructure to collect 
representative data and, in return, these developers would utilize the data that is 
collected to train their medical AI.113 
Another approach to reducing contextual and racial bias in medical AI involves 
revamping the way in which the FDA provides approval for these technologies. The 
FDA should require evidence of the degree of agreement between performance of 
the AI where it was first developed versus performance in a setting different from 
the initial environment. A requirement to demonstrate cross-context effectiveness 
can prevent developers from hiding potential biases embedded within the AI and 
discourage them from solely creating these models in high-resource settings.114 Plus, 
the FDA should establish requirements that force developers to disclose the data that 





111 Id. at 109. 
112 Id. at 110. 
113 Id. 
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their AI has learned from.115 This disclosure should be monitored by relevant third 
parties, such as providers, hospitals, and insurers, alongside supervision by the 
FDA.116 The cooperative strategy could strengthen the FDA’s approval process by 
providing firsthand observations from parties who are active in the field of health 
care.117 This type of approach would emphasize the practicability of post-market 
scrutiny, as opposed to the FDA’s current focus on pre-market examination.118 With 
this strategy in place, the FDA should play the role of an information hub, where it 
can share information gained from AI developers in a usable and comprehendible 
form with the third parties involved, so that they can assess the quality and efficacy 
of the algorithm, in the same way that these actors evaluate different drug or 
treatment alternatives.119 
Similarly, in the E.U., “. . . medical devices are regulated by the Member States 
who can designate independent accredited ‘notified bodies’ to conduct the required 
conformity assessments and by national competent authorities appointed by the 
Member States that are . . . responsible for monitoring notified bod[ies].”120 This 
resembles the approach proposed above in that the European Medicines Agency, 
comparable to the FDA in the U.S., is not the sole regulator of medical devices. It 
employs designated bodies that conduct the approval process. The E.U. approach 
differs in that these bodies are not active market players such as hospitals and 
providers. 
However, forcing AI developers to disclose the data and methods on which 
their medical AI was trained on seemingly eliminates any incentive for producing 
the AI because disclosure takes away any competitive advantage the developers may 
have had. Therefore, there must be some kind of protection for developers in order 
to preserve their incentive to create medical AI. 
One proposal is to allow for a delay in disclosure, so that fast-moving 
companies can acquire first-mover advantages and can build their models before 
possible adversaries can see the disclosed information.121 Nevertheless, this approach 
could cause a delay in the cooperative regulatory strategy proposed above, in that the 
information would not become available to the involved third parties until much later 
                                                          
115 Price II, Regulating Black-Box Medicine, supra note 81, at 421. 
116 Id. at 424. 
117 Id. at 458. 
118 Id. 
119 Id. 
120 Minssen et al., supra note 4, at 14. 
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in the approval process.122 Another option for disclosure is that data could be 
examined by the regulatory bodies, but not used as the foundation for competitors’ 
algorithms for a certain period of time, like a patent.123 
A few miscellaneous suggestions that do not fall within the FDA’s authority 
include designing algorithms that can audit other AI for bias, establishing an 
independent agency outside of Health and Human Services (HHS) for AI regulations 
in general, and addressing racial bias in algorithms through anti-discrimination 
law.124 The first would involve significant investment, either private or public, in 
creating a whole new type of algorithm that would be run against all newly developed 
medical AI in order to evaluate for contextual and racial bias. The second would 
require an enormous overhaul in the current system and legislation authorizing a new 
body to take control over AI regulation. While it is a drastic measure, establishing 
an independent body to regulate AI would clear up the confusion with the FDA’s 
“medical devices” and “practice of medicine distinction,” and it would streamline 
the process of getting AI approved without changing the system for any other product 
that requires approval from the FDA. The third would call for a private cause of 
action for disparate impact discrimination.125 
An article by Hoffman and Podgurski argues that discriminatory medical AI 
“. . . can violate civil rights laws such as Title VI and Section 1557 of the Affordable 
Care Act (ACA) when it exacerbates health disparities or perpetuates inequities.”126 
If health care providers do not act in good faith or act with deliberate indifference to 
medical AI’s potential discriminatory impacts, they may encounter intentional 
discrimination suits.127 Yet medical AI can also give rise to unintentional 
discrimination when algorithms which seem neutral on their face harm certain 
communities/populations.128 Here, the relevant cause of action is disparate impact.129 
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125 Hoffman & Podgurski, supra note 124, at 30. 
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The disparate impact theory allows plaintiffs to bring claims for discrimination 
without being required to show an intent to discriminate.130 
Unfortunately, in Alexander v. Sandoval, the Court held that private citizens 
cannot bring disparate impact claims under Title VI, and only the government can 
bring forward disparate impact concerns.131 Additionally, it is unclear whether 
§ 1557 of the ACA allows for disparate impact claims.132 Courts have come to mixed 
holdings on this issue. The authors above contend that with the recent proliferation 
of AI, it is unreasonable to bar private citizens from pursuing disparate impact claims 
in the health care sphere, especially because government enforcement of disparate 
impact cases is contingent on political priorities.133 
While I commend Hoffman and Podgurski’s approach of adapting anti-
discrimination law to combat racism in medical AI, I do not think it can be practical 
in the real world. The proposed change in Title VI to accommodate private citizens’ 
disparate impact claims sweeps too broadly, as Title VI applies to any program 
receiving federal funding. If there was a way to limit allowance of disparate impact 
claims solely to those involving medical AI, Hoffman and Podgurski’s proposal 
would be an ideal solution. However, it is impractical to broadly permit any and all 
disparate impact claims under Title VI, especially considering that the Court in 
Alexander v. Sandoval held there is no evidence that Congress intended to create a 
private cause of action.134 The Court looks to what party the statute focuses on in its 
definition of the specific regulation.135 In § 602, the statute’s focus is on neither the 
individuals protected nor the regulated entity itself.136 Rather, the focus is on “the 
agencies that will do the regulating.”137 This focus is so far removed from the private 
individuals that the statute intends to protect and thus leads the Court to believe that 
Congress did not intend to establish a private cause of action for disparate impact 
cases.138 
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As a result, this solution would require Congress to amend the Civil Rights Act 
significantly—something that is unlikely to happen. Noting that the probability of 
such a consequential amendment is low, the only other way Hoffman and 
Podgurski’s proposal would be feasible is if Congress legislates carve-outs in Title 
VI that would allow disparate impact claims for health care-related AI issues. While 
this may sound optimal, it will be very difficult to draw the line at which carve-outs 
should and should not be allowed. This can lead to a slippery slope of allowing too 
many carve-outs and thus changing Congress’s intent in passing Title VI. Therefore, 
I find that the approach I propose, which consists of a public data infrastructure and 
an overhaul of the FDA’s approval system specifically for AI, is preferable to an 
antidiscrimination approach. 
All in all, medical AI can be influenced greatly by factors like access to 
resources, staffing, skills, training, and workflow.139 AI also diverges from other 
medical devices because it can continuously learn, it has the capability to be 
omnipresent in medical relationships, and the way it makes decisions is likely 
ambiguous to its users.140 We also need to consider the technology’s interactions 
with other aspects of providing care, including “. . . the payment structure, data 
providers, software components provider, and trainers.”141 As a result, the whole 
system must be evaluated as a complex entity, through a systems approach.142 That 
is the benefit of regulating these technologies through a cooperative strategy, as it 
enables relevant market actors, who have hands-on experience with the AI and 
contribute to the entire system, to play a role in the approval process. 
VI. CONCLUSION 
While medical technology continues to advance at astounding rates, these 
developments may come at a cost to particular members of our society. Medical AI 
has proven to be beneficial in administrative, custodial, caregiving, research, 
imaging, and diagnosis settings; however, these algorithms have also been 
exacerbating racism in the medical field. Due to data that is not representative of 
patient populations and racial bias already present in medicine, medical AI has 
learned to discriminate against minority populations. Current regulatory schemes fail 
to prevent or reduce this discrimination. Therefore, the FDA must rethink its strategy 
for regulating medical AI, possibly by investing in data infrastructure to reduce 
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inequities in the availability of resources, requiring developers to disclose pertinent 
data, or implementing various other means to eliminate racial bias in medical AI. In 
the future, AI may become a universal mechanism in the field of public health in 
order to recommend how to diminish social determinants of health and promote 
health equity, but for now, the pressure is on for regulatory bodies to make sure that 
medical AI is both available and beneficial to each and every member of our 
community. 
